RetractedArticleThe Journal of clinical investigation2011

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Stephanie K Watkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.